PDS Biotech publishes shareholder letter on strategic refocus to PDS0301
PDSB•Phase 2 data and next steps
The letter cited Phase 2 mCRC data showing a 71% objective response rate at 6 months and 80% 24-month survival in MSS/pMMR patients with liver metastases.
A randomized Phase 2b program for PDS0301 is planned and designed with FDA feedback, with milestones targeted over the next 18-24 months.
Strategic refocus to prioritize PDS0301
PDS Biotechnology issued a shareholder letter outlining a strategic refocus to prioritize PDS0301 in metastatic colorectal cancer.
Internal spending on PDS0101 will stop, including discontinuation of the Phase 3 VERSATILE-003 trial; partnering will be sought for further development.
